What Lomexin Treats: Main Uses and Benefits

Lomexin (Fenticonazole) is a medication used to manage conditions caused by yeast and other susceptible fungi. It is applied across domains where short-term symptomatic assistance is needed, and is commonly used to help with vulvovaginal candidiasis (a common yeast infection). The active substance is considered relevant for easing discomfort associated with localized conditions.

---

Easing Noticeable Discomfort and Symptom Intensity

Lomexin is relevant for managing symptom clusters that may become intense or disruptive and are associated with episodic changes. It is applied during phases where symptoms related to physical discomfort—such as itching, burning, and soreness—interfere with daily functioning. Providing supportive relief that helps ease the overall symptom load, the medication supports patients during episodes of heightened discomfort. It is relevant in contexts involving heightened systemic burden.

---

Quick Fact: Symptomatic Relief for Fungal Conditions

This supportive relief may assist with maintaining functional stability when symptoms become more noticeable, helping patients cope more steadily with symptom fluctuations. Lomexin is commonly used in clinical settings that involve acute or unstable symptom patterns, where temporary symptomatic support is appropriate.

Regulatory References

1. Base de Données Publique des Médicaments

Lomexin (Fenticonazole) eligibility is determined by official regulatory documents based on age, physiological status, and concurrent product use.

Contraindications and Absolute Exclusions

• The medicine is contraindicated and must not be used by patients with a known hypersensitivity to fenticonazole, other imidazole derivatives, or any inactive ingredient in the product.
• Lomexin vaginal capsules must not be used concurrently with latex barrier contraceptives (such as condoms or diaphragms), as the product's excipients may damage the latex material. Concurrent use with spermicides or vaginal douches is also restricted.

Restricted and Age-Group Eligibility

The medicine is intended for use in adults and adolescents aged 16 years and over. Use in children under 16 years is not established and therefore not recommended.

Pregnancy and Lactation: Use during both pregnancy and breastfeeding is restricted. Official labeling specifies that the medicine should be used only under the supervision of a physician. The vaginal applicator is prohibited for use during pregnancy.

Conditional Use: Patients who are over 60 years of age, have recurrent symptoms, or have a history of a sexually transmitted disease are required to consult a physician prior to using the product. No specific restrictions are documented for patients with hepatic or renal impairment.

Interactions with other medicines and products

Regulatory documentation for Fenticonazole nitrate (Lomexin) in its topical forms indicates that the interaction profile is predominantly defined by local restrictions rather than systemic drug-drug interactions.

Following topical application, the systemic absorption of Fenticonazole is minimal. As a result, official regulatory sources report no documented metabolic or transporter-mediated interactions with systemically administered oral or injectable medicines, including those mediated by CYP enzymes.

---

Official Interaction Restrictions

Interactions involving Lomexin are primarily physical or chemical, leading to mandated restrictions on co-administered local products:

• Latex Barrier Contraceptives: Use with latex male condoms or vaginal diaphragms is restricted or contraindicated. The fatty excipients and oils present in the vaginal soft capsules (ovules) and cream may cause damage or degradation to the latex material, potentially leading to mechanical failure of the contraceptive device.
• Spermicidal Products: Co-use with spermicidal products is restricted. Any local vaginal treatment may inactivate the spermicidal agent, resulting in a loss of the product’s contraceptive efficacy.

No mandatory administration timing rules are specified for separation from systemic medications. The documented constraints relate solely to the simultaneous use of these specific local products.

How Lomexin Works

Lomexin, containing fenticonazole, acts through a multi-modal mechanism that disrupts the fungal organism's structure, metabolism, and virulence factors.

---

Inhibition of Fungal Cell Membrane Construction

The primary mechanism involves non-competitive inhibition of the fungal enzyme lanosterol 14-alpha-demethylase. This blocks the conversion of lanosterol into ergosterol , a vital component of the fungal cell membrane, leading to its functional and structural breakdown. This depletion, coupled with the accumulation of toxic precursor sterols, results in fungicidal activity (cell death) and fungistatic activity (growth inhibition).

---

Disruption of Respiration and Virulence

Fenticonazole possesses ancillary mechanisms that disrupt the fungus's energy and defense systems. It blocks fungal cytochrome oxidases and peroxidases, interfering with the respiratory chain and causing metabolic failure. Furthermore, the drug limits the secretion of Secreted Aspartyl Protease (SAP), an enzyme used by Candida species to adhere to and penetrate host tissue. This multi-pronged action contributes to organism elimination and virulence reduction, resulting in an effect profile that includes susceptible bacteria and protozoa.

How to Use Lomexin (Fenticonazole Nitrate): Official Administration Guidelines

Lomexin (fenticonazole nitrate) is administered via the intravaginal route using capsules or cream for primary use, or the topical route for skin applications. The usage protocol is defined by specific short-term dosing schedules, focusing on localized treatment patterns derived from prescribing information.

---

Standard Dosing Regimens

The official regimens for intravaginal use are structured to allow for either a single intensive application or a short, multi-day course:

• Single-Dose: One 600 mg vaginal capsule is administered once only.
• Multi-Day Course: One 200 mg vaginal capsule is administered once daily for three consecutive days, or one applicatorful (approx 5 g) of the 2% vaginal cream is administered twice daily for three days.

These applications are typically performed at bedtime to promote optimal drug retention, with the capsule or cream inserted deeply into the vagina.

---

Population Rules and Constraints

Administration rules specify limitations for certain patient groups. The use of Lomexin is not recommended for children and adolescents under 16 years of age. Additionally, the oily excipients in the vaginal forms may damage latex contraceptives (condoms and diaphragms), necessitating the use of alternative contraceptive methods during the administration period. The course of administration should be completed as prescribed, regardless of whether symptoms subside rapidly.

Research evidence / Overview of studies for Lomexin

Evidence for use in Acute Vulvovaginal Candidiasis

Research exploring the use of Fenticonazole for common yeast infections, known as Acute Vulvovaginal Candidiasis (VVC), is primarily based on Randomized Controlled Trials (RCTs). These studies were designed to compare Fenticonazole with other specific topical treatments or non-active comparators. Researchers monitored two main types of outcomes: mycological endpoints (clearance of the fungal pathogen), which involve lab tests, and clinical endpoints, which monitor changes in patient-reported symptoms like itching, burning, and soreness.

The research so far describes patterns related to the measured mycological and symptom endpoints within the first week following the completion of treatment. These short-term measurements have been reported across various trials. Findings were observed in studies exploring patient-reported experiences relevant to trials assessing short-term or episodic symptom patterns.

Evidence contributes to the broader landscape of treatments for these conditions. Findings were sometimes mixed across studies, particularly when research explored conditions involving both fungi and certain bacteria or protozoa (mixed infections).

---

Evidence for use in Superficial Cutaneous Mycoses

Research has also explored the use of Fenticonazole cream for conditions characterized by fungal infections affecting the skin, known as Superficial Cutaneous Mycoses. The evidence for this use derives mostly from comparative clinical trials, where Fenticonazole was studied alongside other specific topical antifungal creams. These studies monitored changes in outcomes linked to inflammatory or irritative states.

In this research, studies monitored clinical endpoints by grading the resolution of visible skin signs such as redness and scaling. They also examined mycological endpoints (elimination of the fungal elements) by verifying the absence of the pathogen from skin samples. Data describe patterns related to how symptoms were reported in the observed populations, and findings help contextualize how patients reported their experience during these short-term studies.

---

Long-term Studies and Durability of Response

Clinical trials examining Fenticonazole primarily focus on short-term outcomes and intermediate follow-up durations. The research explored short-term symptom changes, with typical follow-up periods ranging from one week to about four weeks (28 days) post-treatment completion.

Studies have monitored the frequency of relapse or recurrence within these defined time intervals. However, there is limited information for long-term outcomes and the durability of the initial measurement of change beyond these early assessment periods. Long-term effects are not fully established, and additional research is needed to characterize outcomes extending over many months.

---

Research Focus on Specific Patient Groups

Data for certain groups remain insufficient. Specifically, there is limited information available from high-quality trials for patient populations with recurrent VVC or those whose condition may be compromised by other conditions. Because results apply only to the populations studied, these findings do not determine whether an individual who falls outside the typical trial parameters will respond similarly.

---

What Research Gaps and Uncertainties Remain

While research provides context for understanding symptom patterns in common fungal conditions, certainty remains low in several areas. Evidence quality varies across studies, with some relying on modest sample sizes or older trial designs. Research provides insight into short-term changes, but more research is needed for recurrent, severe, or immunocompromised conditions to address the overall functional and systemic outcomes reflecting longer-term management.

Common questions about Lomexin (FAQ)

---

Q: Is Lomexin the same kind of medicine as clotrimazole or miconazole?

Official information indicates that Fenticonazole, the active ingredient in Lomexin, belongs to the imidazole derivative class of antifungal agents. This is the same chemical classification as medicines like clotrimazole and miconazole. Therefore, they share a common structural and functional drug type.

Q: Are there any common foods or drinks to avoid while using Lomexin?

Because the medicine is used topically (applied directly to the affected area) and has minimal systemic absorption, official documents do not list any necessary restrictions or required separation from common foods or drinks.

Q: How quickly is Lomexin expected to start working?

Research and official documents monitored clinical efficacy, which refers to the monitoring of symptom changes, which was generally observed within a few days of commencing treatment in studies. The exact timing can vary.

Q: What should be done if a dose of Lomexin is missed?

Regulatory sources generally advise skipping the missed dose and continuing with the regular schedule. It is advised not to attempt to use extra medicine to compensate for the missed dose.

Q: Is Lomexin approved for use in women who are pregnant or breastfeeding?

Official labeling restricts the use of Lomexin during both pregnancy and breastfeeding. The medicine should only be used under the supervision of a physician.

Q: Can Lomexin interact with common painkillers like ibuprofen or acetaminophen?

Due to its minimal systemic absorption when applied topically, official documentation reports no documented metabolic or transporter-mediated interactions. This means there are typically no expected drug interactions with systemically administered oral medicines, such as common painkillers.

Q: Are there any specific warnings about using Lomexin if I have a liver condition?

Official regulatory documents do not specifically list restrictions or required dosing adjustments for patients who have hepatic (liver) impairment.

Q: Is the sensation of discharge or leakage normal when using the ovules?

The vaginal capsules (ovules) are formulated with a fatty or lipid excipient base that is designed to melt. Some discharge or leakage may be observed, as this is consistent with the melting characteristics of the formulation's lipid base.

Q: Does regulatory evidence show that Lomexin works well for its intended use?

Official research evidence and clinical trials monitor specific outcomes for the drug’s approved uses. These outcomes include mycological endpoints (the clearance of the fungal pathogen) and clinical endpoints (changes in patient-reported symptoms) over short-term observation periods.

Q: What happens if Lomexin is accidentally swallowed?

Safety data sheets describe the procedure for accidental ingestion as rinsing the mouth with water and avoiding induction of vomiting. These documents also recommend immediately contacting a doctor or Poison Control Center.

Q: Is there a generic version of Lomexin, and is it the same?

Lomexin is the trade name for the active ingredient Fenticonazole nitrate. While various generic products contain the same active substance, official documents note that the inactive ingredients, or excipients, may vary between different product brands.

Q: Why do some instructions mention avoiding intercourse during treatment with Lomexin?

Official guidance mandates the avoidance of latex contraceptives (condoms and diaphragms) and spermicidal products during treatment. This is because the fatty excipients in the medicine can cause damage to the latex material and potentially inactivate the spermicidal agent.

Q: Are there different brand names for the same medicine as Lomexin?

Yes, the active ingredient Fenticonazole nitrate is marketed under several different trade names depending on the country or region of sale, but the active medicine remains the same.

Q: Can Lomexin be used by men to treat a fungal infection?

In addition to vulvovaginal candidiasis, official research also explores the use of Fenticonazole for treating superficial cutaneous mycoses, which are fungal infections of the skin that can affect both men and women.

Q: How does the time of day affect when Lomexin should be used?

Official instructions advise administration at bedtime. This timing is recommended to help promote optimal drug retention within the application area.

Q: Is there a list of ingredients in Lomexin besides the active medicine?

Official product documents list the active substance, Fenticonazole nitrate, along with various inactive ingredients known as excipients. These can include components like Wool Fat, Almond oil, Propylene glycol, and Cetyl alcohol, depending on the specific dosage form (e.g., cream or ovule).

Q: Do studies suggest any specific demographic responds better to Lomexin treatment?

Official research context states that findings from clinical trials only apply to the specific populations that were studied. Results do not determine whether individuals outside those typical trial parameters will respond similarly.

Q: What research themes are commonly explored regarding Lomexin?

Common research themes include comparisons of fenticonazole with other topical treatments, monitoring mycological clearance of the fungal pathogen, and assessing changes in patient-reported symptoms like itching and burning.

Q: Is it possible to be allergic to Lomexin?

Official documents state that the medicine is contraindicated (must not be used) if a patient has a known hypersensitivity, or allergic reaction, to Fenticonazole, other related imidazole derivatives, or any of the inactive ingredients.

Q: What information do official sources provide about long-term use of Lomexin?

Regulatory documents indicate that clinical trials primarily focused on short-term outcomes. Consequently, information regarding long-term use and the durability of the response beyond the initial assessment periods is currently limited.

Q: Does the efficacy of Lomexin vary depending on the strain of yeast causing the infection?

Fenticonazole is described in official sources as having broad-spectrum activity. This means it is active against a range of organisms, including the most common type, Candida albicans, as well as other yeasts that can cause infection.

Q: What is the shelf life of Lomexin before it expires?

Official documentation indicates that the unopened product generally has an official shelf life of up to 3 years. However, specific instructions govern the 'in-use' stability and shelf life of the cream after the tube has been opened for the first time.

Q: Does regulatory agencies specify a minimum age for using Lomexin?

Regulatory documents specify that the medicine is intended for use in adults and adolescents aged 16 years and over. Use in individuals under the age of 16 is not established and is therefore not recommended.

Q: Can I use Lomexin if I have recently finished a course of oral antibiotics?

Because the medicine is applied topically and has minimal systemic absorption, official documents do not report drug-drug interactions with systemically administered oral medicines like antibiotics.

Q: Is it mandatory to complete the full course of Lomexin, even if symptoms improve quickly?

Official administration instructions state that the course of the medicine should be completed exactly as prescribed, regardless of whether the symptoms appear to subside rapidly.

Storage and Disposal Requirements

Official regulatory documents mandate specific conditions for storing and disposing of Lomexin (fenticonazole nitrate) to maintain its quality and safety profile.

Classification	Official Regulatory Requirement
Storage Temperature	No special storage conditions are required for the finished product in some regions, though storage is generally maintained below 30 C to ensure stability.
Protection & Handling	Keep the medicine out of the sight and reach of children.
In-Use Stability	Lomexin cream can be used for 30 days after the first opening of the tube.

Disposal Instructions

Unused or expired Lomexin must not be thrown away with household waste or flushed down the sink or toilet. Proper disposal should be carried out through a local pharmaceutical waste take-back scheme or as advised by a pharmacist, which helps protect the environment. Disposal must always be in accordance with local regulations.